An Open-Label, Multicenter, Phase I/II Dose Escalation Study of Oral GW572016 in Combination With Docetaxel (Taxotere) Plus Trastuzumab (Herceptin) in Subjects Previously Untreated for ErbB2-Overexpressing Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Lapatinib (Primary) ; Docetaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 25 Jun 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2018.